Xiaoli Hou

Hydrogen-bond interfacial engineering of silk fibroin-strengthened magnetic colloidal hydrogel for embolization and magnetothermal therapy of hepatocellular carcinoma

Bing Chen, Xingyu Liu, Jinlong Hu, Yonghong Song et autres

cn (code pays fourni par la source)

Abstract 5397: A novel anti-CD3×CD28×STEAP1 tri-specific T-cell engager with enhanced and durable antitumor responses in prostate cancer.

Ge Song, Aiying Xiong, Seng Zhu, Xuemei Tian et autres

Abstract Introduction: Limited efficacy has been achieved with immunotherapy for prostate cancer, largely due to an immunosuppressive or “immune desert” tumor microenvironment, poor T-cell infiltration, or lack of robust tumor-specific targets. To overcome these barriers, we have developed an anti-CD3×CD28×STEAP1 tri-specific T-cell …

A multicenter, randomized phase 2 study evaluating the efficacy and safety of HLX43 (an anti-PD-L1 ADC) in recurrent/metastatic esophageal squamous cell carcinoma.

Linlin Wang, Qi Dang, Yuan Yuan, Yunjian Huang et autres

364 Background: Chemotherapy is the predominant treatment option for patients with advanced ESCC following disease progression on first-line chemoimmunotherapy, which has limited efficacy. HLX43 is a novel antibody-drug conjugate targeting the programmed cell death-ligand 1 (PD-L1). Its promising efficacy alongside good tolerability …

cn (code pays fourni par la source)

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study

Xuezhi Hao, Lin Wang, Yanrong Hao, Yanping Hu et autres

Background: ASTRUM-002 met the primary endpoint of progression-free survival (PFS) with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. Here, we report the results of the final survival analysis. Methods: A total of 636 patients with treatment-naïve, …

cn, us, hk (code pays fourni par la source)

A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors.

Jie Wang, Rui Wan, Shan Zeng, Lin Wu et autres

3025 Background: Antigens highly expressed in tumors such as HER2 and TROP2 have been widely investigated as antibody-drug conjugate (ADC) targets, leading to their approval for various cancers due to their promising efficacies. However, limited targets for approved ADCs and resistance to …

cn (code pays fourni par la source)

Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma

Zhenggang Ren, Guoliang Shao, Jie Shen, Li Zhang et autres

INTRODUCTION: This study aimed to evaluate the safety and preliminary efficacy of serplulimab, a novel programmed death-1 inhibitor, with or without bevacizumab biosimilar HLX04 as first-line treatment in patients with advanced hepatocellular carcinoma. METHODS: This open-label, multicenter phase 2 study (clinicaltrials.gov identifier …

cn (code pays fourni par la source)

CRHR1 antagonist alleviated depression-like behavior by downregulating p62 in a rat model of post-stroke depression

Huanhuan Liu, Yunfei Zhang, Xiaoli Hou, Chuanzhou Zhu et autres

cn (code pays fourni par la source)

A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.

Xinxin Cao, Yu Wu, Peng Liu, Tianling Ding et autres

7574 Background: HLX208 is a novel BRAFV600E inhibitor, exhibiting excellent antitumor efficacy in preclinical studies. This phase 2 study aimed to evaluate the efficacy, safety, and pharmacokinetics of HLX208 in adult patients with Langerhans cell histiocytosis (LCH) and/or Erdheim-Chester disease (ECD) harboring …

cn (code pays fourni par la source)

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study

Jusheng An, Xiu-Min Li, Jing Wang, Lijing Zhu et autres

Objective: We report the efficacy and safety of serplulimab, a novel humanized anti-programmed death-1 antibody, plus nanoparticle albumin-bound (nab)-paclitaxel in previously treated patients with programmed death ligand-1 (PD-L1)-positive advanced cervical cancer. Methods: for up to six cycles once every 3 weeks. Primary …

cn, hk (code pays fourni par la source)

Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma

Zhenggang Ren, Guoliang Shao, Jie Shen, Li Zhang et autres

Introduction: Current treatments for patients with previously treated advanced hepatocellular carcinoma (HCC) provide modest survival benefits. We evaluated the safety and antitumor activity of serplulimab, an anti-PD-1 antibody, plus the bevacizumab biosimilar HLX04 in this patient population. Methods: In this open-label, multicenter, …

cn (code pays fourni par la source)